The web Browser you are currently using is unsupported, and some features of this site may not work as intended. Please update to a modern browser such as Chrome, Firefox or Edge to experience all features Michigan.gov has to offer.
Panel Notice
Panel Notice
562633
As of 9/16/21, the Emergency Use Authorization's for both monoclonal antibody therapies (bamlanivimab + etesevimab and REGEN-COV) have been expanded to include post-exposure prophylaxis for individuals who are at high risk for progression to severe COVID-19.